Natural bioactive compounds–The promising candidates for the treatment of intestinal failure-associated liver disease

Gostyńska, Aleksandra; Buzun, Kamila; Żółnowska, Izabela; Krajka-Kuźniak, Violetta; Mańkowska-Wierzbicka, Dorota; Jelińska, Anna; Stawny, Maciej

doi:10.1016/j.clnu.2024.07.004

Clinical Nutrition

2024

DOI: 10.1016/j.clnu.2024.07.004

|View full text |Cite

Natural bioactive compounds–The promising candidates for the treatment of intestinal failure-associated liver disease

Aleksandra Gostyńska,

Kamila Buzun,

Izabela Żółnowska

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Molecular mechanisms underlying hepatoprotective activity of lutein in the context of intestinal failure-associated liver disease

Żółnowska,

Gostyńska-Stawna,

Stawny

2024

Pharmacological Research

View full text Add to dashboard Cite

Molecular mechanisms underlying hepatoprotective activity of lutein in the context of intestinal failure-associated liver disease

Żółnowska,

Gostyńska-Stawna,

Stawny

2024

Pharmacological Research

View full text Add to dashboard Cite

Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Markowska,

Kasprzak-Drozd,

Niziński

et al. 2024

Molecules

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a chronic liver disease. The development of MASLD is influenced by a multitude of diseases associated with modern lifestyles, including but not limited to diabetes mellitus, hypertension, hyperlipidaemia and obesity. These conditions are often consequences of the adoption of unhealthy habits, namely a sedentary lifestyle, a lack of physical activity, poor dietary choices and excessive alcohol consumption. The treatment of MASLD is primarily based on modifying the patient’s lifestyle and pharmacological intervention. Despite the absence of FDA-approved pharmacological agents for the treatment of MASLD, several potential therapeutic modalities have demonstrated efficacy in reversing the histopathological features of the disease. Among the botanical ingredients belonging to the flavonoid group is quercetin (QE). QE has been demonstrated to possess a number of beneficial physiological effects, including anti-inflammatory, anticancer and antifungal properties. Additionally, it functions as a natural antioxidant. Preclinical evidence indicates that QE may play a beneficial role in reducing liver damage and improving metabolic health. Early human studies also suggest that QE may be an effective treatment for MASLD due to its antioxidant, anti-inflammatory, and lipid-regulating properties. This review aims to summarize the available information on the therapeutic effects of QE in MASLD.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Natural bioactive compounds–The promising candidates for the treatment of intestinal failure-associated liver disease

Cited by 2 publications

References 161 publications

Molecular mechanisms underlying hepatoprotective activity of lutein in the context of intestinal failure-associated liver disease

Molecular mechanisms underlying hepatoprotective activity of lutein in the context of intestinal failure-associated liver disease

Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Contact Info

Product

Resources

About